Buscar

Mostrando ítems 1-10 de 18

Impact Of Severe Haemophilia A On Patients' Health Status: Results From The Guardian(™) 1 Clinical Trial Of Turoctocog Alfa (novoeight(®) ).

Ozelo, M; Chowdary, P; Regnault, A; Busk, A K (2015)

Updates From Guardian(™) : A Comprehensive Registration Programme.

Ozelo, Margareth C (2015)

Updates From Guardian (tm): A Comprehensive Registration Programme

Ozelo; Margareth C. (WILEY-BLACKWELLHOBOKEN, 2015)

Results from a large multinational clinical trial (guardian (TM) 3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics

Kulkarni, R; Karim, FA; Glamocanin, S; Janic, D; Vdovin, V; Ozelo, M; Rageliene, L; Carboni, E; Laguna, P; Dobaczewski, G; Seremetis, S; Lindblom, A; Santagostino, E (Wiley-blackwellHobokenEUA, 2013)

Results from a large multinational clinical trial (guardian (TM) 1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy

Lentz, SR; Misgav, M; Ozelo, M; Salek, SZ; Veljkovic, D; Recht, M; Cerqueira, M; Tiede, A; Brand, B; Mancuso, ME; Seremetis, S; Lindblom, A; Martinowitz, U (Wiley-blackwellHobokenEUA, 2013)

Satisfaction Of Young Adults With Haemophilia A Previously Treated With Prophylaxis And Switching To Prophylactic Treatment With Recombinant Factor Viii Turoctocog Alfa

Ozelo; M.; Regnault; A.; Slothuus; U.; Hoxer; C. S. (WILEY-BLACKWELLHOBOKEN, 2015)

Quality Of Life And Satisfaction Of Adults With Haemophilia A Switched To Prophylactic Treatment With Recombinant Factor Viii Turoctocog Alfa

Ozelo; M.; Meunier; J.; Hoxer; C. S.; Slothuus; U. (WILEY-BLACKWELLHOBOKEN, 2015)

Efficacy And Safety Of Turoctocog Alfa For Prophylaxis And Treatment Of Bleeding Episodes In Patients With Severe Hemophilia A: Results From The Guardian (tm) 2 Trial

Janic; Dragana; Karim; Faraizah Abdul; Matytsina; Irina; Ozelo; Margareth Castro; Savic; Aleksandar; Tiede; Andreas; Oldenburg; Johannes (Wiley-BlackwellHoboken, 2016)

Long-term Patterns Of Safety And Efficacy Of Bleeding Prophylaxis With Turoctocog Alfa (novoeight(®) ) In Previously Treated Patients With Severe Haemophilia A: Interim Results Of The Guardian(™) 2 Extension Trial.

Ozelo, M; Misgav, M; Abdul Karim, F; Lentz, S R; Martin-Salces, M; Matytsina, I; Saugstrup, T; Santagostino, E (2015)

Efficacy And Safety Of Turoctocog Alfa For Prophylaxis And Treatment Of Bleeding Episodes In Patients With Severe Hemophilia A: Results From The Guardian (tm) 2 Trial

Janic; D; Karim; FA; Matytsina; I; Ozelo; MC; Savic; A; Tiede; A; Oldenburg; J (WILEY-BLACKWELLHOBOKEN, 2016)

Buscar

Filtros

Impact Of Severe Haemophilia A On Patients' Health Status: Results From The Guardian(™) 1 Clinical Trial Of Turoctocog Alfa (novoeight(®) ).

Updates From Guardian(™) : A Comprehensive Registration Programme.

Updates From Guardian (tm): A Comprehensive Registration Programme

Results from a large multinational clinical trial (guardian (TM) 3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics

Results from a large multinational clinical trial (guardian (TM) 1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy

Satisfaction Of Young Adults With Haemophilia A Previously Treated With Prophylaxis And Switching To Prophylactic Treatment With Recombinant Factor Viii Turoctocog Alfa

Quality Of Life And Satisfaction Of Adults With Haemophilia A Switched To Prophylactic Treatment With Recombinant Factor Viii Turoctocog Alfa

Efficacy And Safety Of Turoctocog Alfa For Prophylaxis And Treatment Of Bleeding Episodes In Patients With Severe Hemophilia A: Results From The Guardian (tm) 2 Trial

Long-term Patterns Of Safety And Efficacy Of Bleeding Prophylaxis With Turoctocog Alfa (novoeight(®) ) In Previously Treated Patients With Severe Haemophilia A: Interim Results Of The Guardian(™) 2 Extension Trial.

Efficacy And Safety Of Turoctocog Alfa For Prophylaxis And Treatment Of Bleeding Episodes In Patients With Severe Hemophilia A: Results From The Guardian (tm) 2 Trial